HeartBeam Future Growth

Future criteria checks 2/6

HeartBeam is forecast to grow revenue at 89.2% per annum. EPS is expected to grow by 6.9% per annum.

Key information

n/a

Earnings growth rate

6.9%

EPS growth rate

Medical Equipment earnings growth	16.6%
Revenue growth rate	89.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	13 May 2024

Recent future growth updates

Recent updates

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

Jan 17

HeartBeam gets a new chief medical officer

Oct 11

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

Sep 28

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Sep 15

HeartBeam GAAP EPS of $0.43 beats by $0.70

Aug 11

HeartBeam: Cardiovascular Diagnostics On The Go

Dec 14

Earnings and Revenue Growth Forecasts

NasdaqCM:BEAT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	12	N/A	N/A	N/A	1
12/31/2025	1	N/A	N/A	N/A	1
3/31/2024	N/A	-15	-13	-12	N/A
12/31/2023	N/A	-15	-12	-12	N/A
9/30/2023	N/A	-14	-12	-12	N/A
6/30/2023	N/A	-15	-13	-13	N/A
3/31/2023	N/A	-15	-11	-11	N/A
12/31/2022	N/A	-13	-10	-10	N/A
9/30/2022	N/A	-11	-9	-9	N/A
6/30/2022	N/A	-9	-7	-7	N/A
3/31/2022	N/A	-6	-5	-5	N/A
12/31/2021	N/A	-4	-3	-3	N/A
9/30/2021	N/A	-3	-1	-1	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-1	-1	-1	N/A
12/31/2020	N/A	-1	-1	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BEAT's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if BEAT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if BEAT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BEAT's revenue (89.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: BEAT's revenue (89.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BEAT's Return on Equity is forecast to be high in 3 years time

HeartBeam Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 38% to US$5.00

No longer forecast to breakeven

Recent updates

HeartBeam, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

HeartBeam, Inc., Annual General Meeting, Jun 12, 2024

HeartBeam, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 38% to US$5.00

High number of new and inexperienced directors

HeartBeam, Inc. Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

HeartBeam, Inc. Announces First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo System for Synthesizing A 12-Lead ECG

HeartBeam, Inc. Receives Two New US Patents for Its Core Cardiac Monitoring Technology

HeartBeam, Inc. to Report Q4, 2023 Results on Mar 20, 2024

HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer

HeartBeam, Inc. Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

HeartBeam, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Heartbeam, Inc. Appoints Richa Gujarati as Senior Vice President, Product

HeartBeam, Inc. Appoints Michael R. Jaff to the Board of Directors

Less than half of directors are independent

Heartbeam Appoints Ken Nelson and Mark Strome to the Board of Directors

HeartBeam, Inc., Annual General Meeting, Jul 07, 2023

HeartBeam, Inc. Announces Automated Cardiac Detection Patent Granted for Heartbeam Aimigo™ System

HeartBeam, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

HeartBeam, Inc. Appoints Robert Eno as President

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

HeartBeam Receives European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam, Inc. Announces Patent for 12-Lead Electrocardiogram Smartwatch-Based Monitor

Less than half of directors are independent

HeartBeam, Inc. to Report Q3, 2022 Results on Nov 10, 2022

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

HeartBeam gets a new chief medical officer

HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

Heartbeam Grants Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Heartbeam Announces FDA Submission of Heartbeam Aimi™ Product

Heartbeam, Inc. Announces Resignation of Alan Baumel as Chief Operating Officer, Effective on August 15, 2022

HeartBeam GAAP EPS of $0.43 beats by $0.70

HeartBeam, Inc. Announces the Appointment of Ken Persen to the Role of Chief Technology Officer

HeartBeam, Inc. to Report Q2, 2022 Results on Aug 11, 2022

HeartBeam, Inc., Annual General Meeting, Jun 15, 2022

No independent directors

HeartBeam, Inc. Announces Board Changes

HeartBeam: Cardiovascular Diagnostics On The Go

Director exercised options to buy US$1.4m worth of stock.

No independent directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies